The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth

Breast Cancer Research and Treatment

Volumn 173, Issue 3, 2019, Pages 545-557

  Bowers, Laura W ^a,b   Lineberger, Claire G ^a   Ford, Nikki A ^c   Rossi, Emily L ^a,b   Punjala, Arunima ^a   Camp, Kristina K ^a   Kimler, Bruce K ^d   Fabian, Carol J ^d   Hursting, Stephen D ^a,b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of Texas at Austin   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Enterodiol (END); Enterolactone (ENL); NF B; Plant lignan; Secoisolariciresinol diglucoside (SDG)

Indexed keywords

LIGNAN SECOISOLARICIRESINOL DIGLUCOSIDE; PLANT MEDICINAL PRODUCT; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; 2,3-BIS(3'-HYDROXYBENZYL)BUTYROLACTONE; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; BUTANEDIOL; CYTOKINE; GAMMA BUTYROLACTONE; GLUCOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGNAN; SECOISOLARICIRESINOL DIGLUCOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST TUMOR; BREAST TUMOR CELL LINE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER SIZE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LINSEED; LOW DRUG DOSE; MACROPHAGE; MAMMARY GLAND FAT; MCF-7 CELL LINE; MDA-MB-231 CELL LINE; MITOSIS INHIBITION; MOUSE; NF KAPPA B SIGNALING; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL MAMMARY NEOPLASM; FLAX; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

4-BUTYROLACTONE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; BUTYLENE GLYCOLS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLAX; GENE EXPRESSION PROFILING; GLUCOSIDES; IMMUNOHISTOCHEMISTRY; LIGNANS; MAMMARY NEOPLASMS, ANIMAL; MICE; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 85055701548     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-018-5021-6     Document Type: Article

References (52)

1. Mazur W (1998) Phytoestrogen content in foods. Baillieres Clin Endocrinol Metab 12:729–742
2. Mazur WM, Wahala K, Rasku S, Salakka A, Hase T, Adlercreutz H (1998) Lignan and isoflavonoid concentrations in tea and coffee. Br J Nutr 79:37–45
3. Borriello SP, Setchell KD, Axelson M, Lawson AM (1985) Production and metabolism of lignans by the human faecal flora. J Appl Bacteriol 58:37–43
4. Buck K, Vrieling A, Zaineddin AK, Becker S, Husing A, Kaaks R, Linseisen J, Flesch-Janys D, Chang-Claude J (2011) Serum enterolactone and prognosis of postmenopausal breast cancer. J Clin Oncol 29:3730–3738
5. Buck K, Zaineddin AK, Vrieling A, Heinz J, Linseisen J, Flesch-Janys D, Chang-Claude J (2011) Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer. Br J Cancer 105:1151–1157
6. Olsen A, Christensen J, Knudsen KE, Johnsen NF, Overvad K, Tjonneland A (2011) Prediagnostic plasma enterolactone levels and mortality among women with breast cancer. Breast Cancer Res Treat 128:883–889
7. Guglielmini P, Rubagotti A, Boccardo F (2012) Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. Breast Cancer Res Treat 132:661–668
8. Seibold P, Vrieling A, Johnson TS, Buck K, Behrens S, Kaaks R, Linseisen J, Obi N, Heinz J, Flesch-Janys D, Chang-Claude J (2014) Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis. Int J Cancer 135:923–933
9. Mabrok HB, Klopfleisch R, Ghanem KZ, Clavel T, Blaut M, Loh G (2012) Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer. Carcinogenesis 33:203–208
10. Lindahl G, Saarinen N, Abrahamsson A, Dabrosin C (2011) Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer. Cancer Res 71:51–60
11. Saarinen NM, Abrahamsson A, Dabrosin C (2010) Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo. Int J Cancer 127:737–745
12. Saarinen NM, Huovinen R, Warri A, Makela SI, Valentin-Blasini L, Sjoholm R, Ammala J, Lehtila R, Eckerman C, Collan YU, Santti RS (2002) Enterolactone inhibits the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in the rat. Mol Cancer Ther 1:869–876
13. Bergman Jungestrom M, Thompson LU, Dabrosin C (2007) Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 13:1061–1067
14. Thompson LU, Seidl MM, Rickard SE, Orcheson LJ, Fong HH (1996) Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr Cancer 26:159–165
15. Power KA, Saarinen NM, Chen JM, Thompson LU (2006) Mammalian lignans enterolactone and enterodiol, alone and in combination with the isoflavone genistein, do not promote the growth of MCF-7 xenografts in ovariectomized athymic nude mice. Int J Cancer 118:1316–1320
16. Chen J, Saggar JK, Corey P, Thompson LU (2009) Flaxseed and pure secoisolariciresinol diglucoside, but not flaxseed hull, reduce human breast tumor growth (MCF-7) in athymic mice. J Nutr 139:2061–2066
17. Saggar JK, Chen J, Corey P, Thompson LU (2010) Dietary flaxseed lignan or oil combined with tamoxifen treatment affects MCF-7 tumor growth through estrogen receptor- and growth factor-signaling pathways. Mol Nutr Food Res 54:415–425
18. Delman DM, Fabian CJ, Kimler BF, Yeh H, Petroff BK (2015) Effects of flaxseed lignan secoisolariciresinol diglucosideon preneoplastic biomarkers of cancer progression in a model of simultaneous breast and ovarian cancer development. Nutr Cancer 67:857–864
19. Mali AV, Joshi AA, Hegde MV, Kadam Sh S (2017) Enterolactone suppresses proliferation, migration and metastasis of MDA-MB-231 breast cancer cells through inhibition of uPA induced plasmin activation and MMPs-mediated ECM remodeling. Asian Pac J Cancer Prev 18:905–915
20. Xiong XY, Hu XJ, Li Y, Liu CM (2015) Inhibitory effects of enterolactone on growth and metastasis in human breast cancer. Nutr Cancer 67:1324–1332
21. Johnstone CN, Smith YE, Cao Y, Burrows AD, Cross RS, Ling X, Redvers RP, Doherty JP, Eckhardt BL, Natoli AL, Restall CM, Lucas E, Pearson HB, Deb S, Britt KL, Rizzitelli A, Li J, Harmey JH, Pouliot N, Anderson RL (2015) Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Model Mech 8:237–251
22. Chen J, Thompson LU (2003) Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro. Breast Cancer Res Treat 80:163–170
23. Mali AV, Wagh UV, Hegde MV, Chandorkar SS, Surve SV, Patole MV (2012) In vitro anti-metastatic activity of enterolactone, a mammalian lignan derived from flax lignan, and down-regulation of matrix metalloproteinases in MCF-7 and MDA MB 231 cell lines. Indian J Cancer 49:181–187
24. Bigdeli B, Goliaei B, Masoudi-Khoram N, Jooyan N, Nikoofar A, Rouhani M, Haghparast A, Mamashli F (2016) Enterolactone: A novel radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis. Toxicol Appl Pharmacol 313:180–194
25. Di Y, De Silva F, Krol ES, Alcorn J (2018) Flaxseed lignans enhance the cytotoxicity of chemotherapeutic agents against breast cancer cell lines MDA-MB-231 and SKBR3. Nutr Cancer 70:306–315
26. Yang Y, Yang HH, Hu Y, Watson PH, Liu H, Geiger TR, Anver MR, Haines DC, Martin P, Green JE, Lee MP, Hunter KW, Wakefield LM (2017) Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. Oncotarget 8:30621–30643
27. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Petroff BK, Khan QJ, Sharma P, Setchell KD, Zhao X, Phillips TA, Metheny T, Hughes JR, Yeh HW, Johnson KA (2010) Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside. Cancer Prev Res (Phila) 3:1342–1350
28. Setchell KD, Brown NM, Zimmer-Nechemias L, Wolfe B, Jha P, Heubi JE (2014) Metabolism of secoisolariciresinol-diglycoside the dietary precursor to the intestinally derived lignan enterolactone in humans. Food Funct 5:491–501
29. Rossi EL, Dunlap SM, Bowers LW, Khatib SA, Doerstling SS, Smith LA, Ford NA, Holley D, Brown PH, Estecio MR, Kusewitt DF, deGraffenried LA, Bultman SJ, Hursting SD (2017) Energy balance modulation impacts epigenetic reprogramming, ERα and ERβ expression, and mammary tumor development in MMTV-neu transgenic mice. Cancer Res 77:2500–2511
30. Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L, Hursting SD (2012) Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res (Phila) 5:930–942
31. Mueller SO, Simon S, Chae K, Metzler M, Korach KS (2004) Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 80:14–25
32. Carreau C, Flouriot G, Bennetau-Pelissero C, Potier M (2008) Enterodiol and enterolactone, two major diet-derived polyphenol metabolites have different impact on ERalpha transcriptional activation in human breast cancer cells. J Steroid Biochem Mol Biol 110:176–185
33. Bowers LW, Cavazos DA, Maximo IX, Brenner AJ, Hursting SD, deGraffenried LA (2013) Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression. Breast Cancer Res 15:R59
34. Bowers LW, Rossi EL, McDonell SB, Doerstling SS, Khatib SA, Lineberger CG, Albright JE, Tang X, deGraffenried LA, Hursting SD (2018) Leptin signaling mediates obesity-associated CSC enrichment and EMT in preclinical TNBC models. Mol Cancer Res 16:869–879
35. Rickard SE, Yuan YV, Chen J, Thompson LU (1999) Dose effects of flaxseed and its lignan on N-methyl-N-nitrosourea-induced mammary tumorigenesis in rats. Nutr Cancer 35:50–57
36. Harvey AE, Lashinger LM, Hursting SD (2011) The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci 1229:45–52
37. Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938–6947
38. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE (1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952–2960
39. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639
40. Biswas DK, Cruz AP, Gansberger E, Pardee AB (2000) Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 97:8542–8547
41. Seo HS, Choi HS, Choi HS, Choi YK, Um JY, Choi I, Shin YC, Ko SG (2011) Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-kappaB signaling in HER2-overexpressing breast cancer cells. Anticancer Res 31:3301–3313
42. Valachovicova T, Slivova V, Bergman H, Shuherk J, Sliva D (2004) Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent and -independent pathways. Int J Oncol 25:1389–1395
43. Banerjee S, Li Y, Wang Z, Sarkar FH (2008) Multi-targeted therapy of cancer by genistein. Cancer Lett 269:226–242
44. Christian F, Smith EL, Carmody RJ (2016) The regulation of NF-kappaB subunits by phosphorylation. Cells 5
45. Jaskulski S, Jung AY, Behrens S, Johnson T, Kaaks R, Thone K, Flesch-Janys D, Sookthai D, Chang-Claude J (2018) Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: assessment of mediation by inflammatory markers. Int J Cancer
46. Gu JW, Young E, Patterson SG, Makey KL, Wells J, Huang M, Tucker KB, Miele L (2011) Postmenopausal obesity promotes tumor angiogenesis and breast cancer progression in mice. Cancer Biol Ther 11:910–917
47. Ke JY, Banh T, Hsiao YH, Cole RM, Straka SR, Yee LD, Belury MA (2017) Citrus flavonoid naringenin reduces mammary tumor cell viability, adipose mass, and adipose inflammation in obese ovariectomized mice. Mol Nutr Food Res 61
48. Wang L, Chen J, Thompson LU (2005) The inhibitory effect of flaxseed on the growth and metastasis of estrogen receptor negative human breast cancer xenograftsis attributed to both its lignan and oil components. Int J Cancer 116:793–798
49. Chen J, Wang L, Thompson LU (2006) Flaxseed and its components reduce metastasis after surgical excision of solid human breast tumor in nude mice. Cancer Lett 234:168–175
50. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081
51. Buck K, Zaineddin AK, Vrieling A, Linseisen J, Chang-Claude J (2010) Meta-analyses of lignans and enterolignans in relation to breast cancer risk. Am J Clin Nutr 92:141–153
52. Zaineddin AK, Vrieling A, Buck K, Becker S, Linseisen J, Flesch-Janys D, Kaaks R, Chang-Claude J (2012) Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status. Int J Cancer 130:1401–1410